. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Clin Transl Oncol. 2018 May 7;20(11):1474–1483. doi: 10.1007/s12094-018-1888-2

Table 4.

Changes in Blood Markers (N=12) in MK-2206 Treated Patients and Prospectively Accrued Untreated Controls (n=5)

Variable	Mean Treatment Pre-MK-2206 (SD)	Mean Treatment Post-MK-2206 (SD)	Paired t test p-value^a	Mean Control Baseline (SD)	Mean Control Level at Surgery (SD)	Paired t test p-value^a	Overall t test p-value^b
Insulin (uIU/mL)	10 (7)	41 (27)	<0.01^*	9 (6)	7 (5)	0.41	<0.01^*
Glucose (mg/dL)	89 (19)	116 (43)	<0.01^*	82 (19)	80 (19)	0.80	0.02^*
C-Peptide (ng/mL)	2 (1)	6 (3)	<0.01^*	2 (1)	2 (1)	0.43	<0.01^*
C-Reactive Protein (mg/L)	4 (4)	11 (17)	0.17	3 (3)	8 (14)	0.42	0.84
IGFBP-3 (ug/mL)	4 (1)	5 (2)	0.08^**	4 (1)	4 (0.4)	0.31	0.06^**

IGF BP-3=I nsul in-Like Gro wth Factor Binding Protein 3

Paired T-test comparing changes within group (example: pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue)

Two-sided t-test comparing changes between MK-2206-treated samples versus control

Paired t-test, significance defined as p < 0.05

^**

Paired t-test, trend toward significance